Progesterone is a hormone produced primarily by the ovaries after ovulation and by the placenta during pregnancy. Men and postmenopausal women produce small amounts from the adrenal glands. Its name reflects its function. It prepares and maintains the uterine lining for pregnancy.
For premenopausal women, progesterone levels indicate whether ovulation is occurring. A luteal-phase level above 10 ng/mL typically confirms ovulation. Progesterone supports mood, sleep, and bone density, and the estrogen-to-progesterone balance affects many symptoms of PMS and perimenopause. For men, progesterone levels should be low; elevated levels may signal adrenal stress or hormonal imbalance. Testing timing matters: progesterone must be drawn in the luteal phase (days 19-22 of a 28-day cycle) for menstruating women to be interpretable.
Optimal Progesterone: 5-20 ng/mL.
Typically re-tested every 4 weeks.
Because levels swing enormously across the menstrual cycle, the date of the blood draw carries as much information as the number printed next to it.
Progesterone is a steroid hormone produced mainly by the corpus luteum, the temporary structure an ovary forms from a follicle after it releases an egg.
The body builds it from cholesterol, by way of pregnenolone, and it sits at a junction in steroid metabolism where it also serves as a raw material for cortisol and for androgens. That is why men and postmenopausal women still carry small amounts in the blood, largely from the adrenal glands, even though the ovarian surge is absent.
Once in circulation, progesterone binds progesterone receptors in the lining of the uterus, in breast tissue, in the brain and in bone. In the endometrium its main job is to switch the tissue from a growing, estrogen-driven state into a stable, secretory state that can support an implanting embryo. If no pregnancy occurs, the corpus luteum fades, progesterone falls, and that withdrawal is what triggers a period.
Progesterone also crosses into the brain, where it is converted into neurosteroids such as allopregnanolone that act on GABA-A receptors, the same receptor family involved in calming and sedating signals. Animal research on progesterone and neurosteroid activity suggests this pathway influences behaviour and stress responses rather than acting only on reproductive tissue[1].
Related: Do Males Have Progesterone? (Yes, in Small Amounts)
It matters because progesterone is both a working hormone and an honest signal that ovulation took place, and ovulation is one of the better overall readouts of female endocrine health.
The clearest role is in the uterus. Estrogen builds the endometrium and progesterone matures it and keeps that growth in check. Cycles that run with estrogen exposure and little progesterone are the situation clinicians watch when they think about endometrial changes over years, which is why the balance between the two markers is discussed more often than either alone.
The brain is the second story. Because progesterone metabolites act on GABA-A receptors, their rise and fall across the luteal phase is thought to contribute to shifts in sleep quality, anxiety and emotional reactivity. Imaging research in premenstrual dysphoric disorder suggests that amygdala reactivity to emotional images varies with menstrual cycle phase, which supports the idea that these hormone swings are reflected in brain function rather than being purely subjective[2].
Breast tissue is more contested, and honest reporting means saying so. Reviews of progesterone and breast cancer biology describe it as both a possible promoter and a possible inhibitor depending on context, receptor environment and the specific molecule involved[3]. Research on combined oral contraceptives has examined breast epithelial proliferation in young women, and findings in this area remain an active field rather than a settled one[4]. Natural progesterone and synthetic progestins are not interchangeable in these discussions.
For men, progesterone is a minor circulating steroid with no established standalone health target. It is read as part of the steroid pathway, not as a performance marker.
A typical lab reference range for progesterone is wide because it has to cover both the near-zero follicular phase and the post-ovulation peak in the same interval.
| Group | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Women | 1 to 25 ng/mL | 5 to 20 ng/mL |
| Men | 0.1 to 2 ng/mL | 0.2 to 1.4 ng/mL |
Researchers in Münster, Germany measured progesterone in 220 healthy men aged 20 to 68, 226 women aged 25 to 44 in the follicular or luteal phase, and 103 postmenopausal women aged 49 to 66. Levels stayed low in men, in the follicular phase and after menopause, and rose sharply in the luteal phase.[13]
| Sex | Age | Reference range (ng/mL) |
|---|---|---|
| Men | 20 to 68 | Below 0.86 |
| Women | Follicular phase | Below 1.03 |
| Women | Luteal phase | 1.14 to 20.6 |
| Women | Postmenopausal | Below 0.60 |
Intervals are 2.5th to 97.5th percentiles measured on the Siemens Advia Centaur analyzer, split by sex and by cycle phase (follicular samples taken on days 3 to 5); the same paper reports slightly different limits on a second analyzer. Progesterone results depend heavily on the assay and the day of the cycle, so your own lab's printed range is the one to read your result against.
Reference ranges vary by lab, assay, age and sex, so always compare your value with the interval printed on your own report. FitScript's optimal ranges are optimization targets, not diagnostic cut-offs, and a result outside them is not a diagnosis of anything.
Two points make this marker different from most. First, timing dominates. In a menstruating woman, a sample drawn in the first week of the cycle and a sample drawn roughly a week after ovulation can differ many-fold, and both can be entirely normal. A low value drawn on day 3 says almost nothing about luteal function. Second, progesterone is pulsatile, meaning the corpus luteum releases it in bursts, so two draws hours apart in the same woman on the same day can differ noticeably.
In pregnancy, in postmenopausal women and in anyone using hormonal medication, the usual interpretation of these numbers does not apply, and the result needs to be read in that context by a clinician.
A high progesterone result usually means the sample was drawn when the body was genuinely producing a lot of it, most often the mid-luteal phase or pregnancy, rather than signalling a problem.
People sometimes describe breast tenderness, bloating, drowsiness, a dip in motivation or mild low mood in the days when progesterone peaks. These reports are common and are not themselves a finding on a lab report.
The usual explanations are mundane. A mid-luteal draw is designed to catch the peak. Pregnancy sustains production through the corpus luteum and then the placenta. Exogenous progesterone raises measured levels directly, and pharmacokinetic work on vaginal micronized progesterone products shows how clearly supplementation shifts the blood picture[5]. Controlled ovarian stimulation for fertility care is another, and research on progesterone during stimulation suggests the timing of a rise carries predictive information for cycle outcome in patients with and without endometriosis[6]. Less commonly, labs consider ovarian cysts or adrenal enzyme variants when an unexplained elevation persists.
Long term, an isolated high value in a correctly timed luteal draw is generally a reassuring sign that ovulation occurred. A high result that cannot be explained by cycle phase, pregnancy or medication, especially alongside other abnormal steroid markers, is worth discussing with a clinician rather than repeating indefinitely on your own.
A low progesterone result most often means the draw happened outside the luteal window, or that ovulation did not occur in that cycle.
Reported experiences cluster around cycle irregularity. Short cycles, spotting in the days before a period, heavy or unpredictable bleeding, difficulty conceiving or sustaining an early pregnancy, disrupted sleep and premenstrual mood shifts are the patterns people tend to notice. None of these confirms anything on its own.
Common causes include a follicular-phase draw, anovulatory cycles, perimenopause, menopause, and suppression of the hypothalamic signal that drives ovulation during periods of heavy training, low energy availability or significant stress. Polycystic ovary syndrome is associated with infrequent ovulation and therefore with low luteal progesterone, and a systematic review and meta-analysis of N-acetylcysteine in this population examined ovulation and sex hormone profiles as outcomes, which illustrates how ovulation itself is studied as the target[7]. Thyroid dysfunction and elevated prolactin are also on the list clinicians work through.
The long-term angle has two parts. Repeated cycles without adequate progesterone leave the endometrium under relatively unopposed estrogen, a pattern clinicians monitor over years. For fertility, luteal support is a standard area of study, and reviews of progesterone supplementation around fresh and frozen embryo transfer examine exactly this question of whether the luteal environment is adequate[8].
A suboptimal result is information, not a verdict. Interpreting it needs the cycle day, your symptoms and the markers around it.
Testing conditions change a progesterone result more than almost any other variable, so the first question is always when the blood was drawn.
What to actually do about a pattern belongs in a longer discussion with a clinician who can see the whole panel.
Progesterone is measured as part of a hormone panel from a standard venous blood draw, read alongside the other reproductive and adrenal markers rather than in isolation.
The FitScript membership includes 150+ biomarkers tested per year, which means a hormone marker like this one can be retested across seasons, training blocks and life stages instead of being judged on one snapshot. For a cycling woman, repeat testing timed to the luteal phase is far more informative than a single draw at a convenient moment.
Atlas, FitScript's AI health advisor, interprets the result in context, combining the cycle day, symptoms, related markers and prior results into your FitScript, the personalized output written from your own biology. The framing stays consistent with how a careful clinician would read it. Here is what the value shows, here is what it may reflect, and here is what is worth raising with a provider.
Where a hormone therapy or prescription medication is part of the discussion, a licensed provider reviews the member and decides whether it is appropriate. Nothing on this page determines that, and no dosing or administration guidance belongs in health education.
Progesterone is close to uninterpretable alone, so it is read with the hormones that drive it and the hormones it balances.
Estradiol is the direct counterpart, since the ratio and sequence of these two across a cycle explain more than either value. Luteinizing hormone drives the ovulatory surge that creates the corpus luteum, and follicle-stimulating hormone reflects how hard the brain is pushing the ovary, which becomes especially informative in perimenopause. Pregnenolone sits upstream as a shared precursor in the steroid pathway. Cortisol matters because the adrenal stress axis and the reproductive axis influence each other, and sustained stress physiology is associated with disrupted ovulation. In men, total testosterone is the relevant anchor, with progesterone read only as a minor part of the same pathway.
Each of these has its own detailed page, Estradiol, Luteinizing Hormone, FSH, Pregnenolone, Cortisol and Testosterone Total, and they are measured together on the Hormone Panel for women.
Progesterone rises after ovulation, prepares the uterine lining, acts on the brain through neurosteroid pathways, and falls away to trigger a period when no pregnancy follows. A result is only as good as its timing, so a mid-luteal draw answers a useful question and a random draw often answers none. High values usually reflect cycle phase, pregnancy or medication, while low values most often reflect mistimed testing or a cycle without ovulation. Read it alongside estradiol, LH, FSH and the adrenal markers, and track the trend rather than chasing one number.
This page is educational and is not medical advice. Discuss your own results and any treatment options with a clinician or licensed provider who can see your full history.
The standard approach is a draw roughly seven days after presumed ovulation, which in a regular cycle falls in the mid-luteal window. A sample taken in the first week of the cycle will be low in almost everyone, so it answers a different question. With irregular cycles, timing is harder to estimate and a clinician may suggest repeat draws.
It matures the uterine lining after ovulation so it can support an implanting embryo, supports early pregnancy, and acts on the brain through neurosteroid metabolites that bind GABA-A receptors. It also sits in the steroid pathway as a precursor for cortisol and androgens, which is why small amounts circulate in men as well.
Commonly described patterns include irregular or short cycles, spotting before a period, heavy or unpredictable bleeding, difficulty conceiving, disrupted sleep and premenstrual mood changes. None of these confirms a low level on its own, and a correctly timed blood test plus a clinician's review is what turns symptoms into useful information.
No. A single value reflects one moment, one cycle day and one assay, and progesterone is released in pulses. It is an observation that may point toward anovulation, a mistimed draw, perimenopause or medication effects. Interpreting it requires your cycle details, symptoms and related hormone markers together.
Because a single interval has to cover both the near-zero follicular phase and the post-ovulation peak. A typical lab reference range is around 1 to 25 ng/mL in women, while FitScript's optimal range is 5 to 20 ng/mL, with 0.2 to 1.4 ng/mL as the optimal range in men. Ranges vary by lab, age and sex, and optimal ranges are optimization targets rather than diagnostic cut-offs.
Yes. Combined hormonal birth control suppresses ovulation, so there is no corpus luteum producing progesterone, and progesterone levels are used precisely to confirm that suppression. Injectable progestins and other hormone-active medications change the picture differently again. Always tell the testing team what you are taking so the result is read correctly.
Men carry small amounts, largely from the adrenal glands, and there is no established standalone health target for it. It is read as part of the steroid pathway alongside markers such as total testosterone, pregnenolone and cortisol rather than as a performance or optimization marker in its own right.
Start by checking the cycle day of the draw, any medications and whether the symptoms match. Then bring the result and the surrounding hormone markers to a clinician or licensed provider, who can decide whether a repeat test, further work-up or any therapy is appropriate. A result that comes with worrying symptoms is worth discussing promptly rather than waiting for the next test.
Estradiol, luteinizing hormone, FSH, pregnenolone and cortisol give the surrounding context, and total testosterone is the relevant anchor in men. These are usually drawn together on a hormone panel, because the relationship between them explains far more than progesterone measured alone.